Ureteric Stents

Ureteric Stents Market Outlook

The global ureteric stents market is projected to reach approximately USD 1.5 billion by 2035, growing at a CAGR of around 6.2% during the forecast period from 2025 to 2035. This growth can be attributed to the increasing prevalence of urinary tract disorders, such as kidney stones and urinary strictures, along with advancements in stent technologies. Additionally, the rising geriatric population, who are more prone to such conditions, coupled with the growing demand for minimally invasive surgical procedures, further fuels the market's expansion. The increasing adoption of ureteric stents in outpatient procedures has also been instrumental in driving market growth, enabling faster recovery times and reduced hospital stays. Moreover, technological innovations in stent materials and designs are expected to enhance the effectiveness and comfort of ureteric stents, making them more favorable options for both patients and healthcare providers.

Growth Factor of the Market

The ureteric stents market is primarily driven by the escalating incidence of urological disorders, particularly kidney stones, which are one of the leading causes of ureteric obstruction. As lifestyle changes and dietary habits contribute to the rising cases of obesity, diabetes, and other health issues, the prevalence of kidney stones continues to increase, subsequently boosting the demand for ureteric stenting procedures. Additionally, advancements in medical technology have led to the development of innovative stent designs, including drug-eluting and biodegradable varieties, which are enhancing patient outcomes and satisfaction. Furthermore, the expanding healthcare infrastructure, particularly in emerging economies, is facilitating greater access to advanced medical care, thus propelling the growth of the ureteric stents market. Increased awareness about urological health issues and the importance of early intervention is encouraging more patients to seek treatment, which in turn is driving market expansion. Lastly, the transition towards outpatient care and the adoption of minimally invasive surgical techniques are further contributing to the market's positive outlook.

Key Highlights of the Market

• The global ureteric stents market is projected to reach USD 1.5 billion by 2035.
• Growing prevalence of kidney stones and urinary tract disorders is a primary growth driver.
• Technological advancements in stent designs are enhancing patient outcomes.
• Increasing awareness and healthcare access in emerging economies are promoting market growth.
• The market is expected to grow at a CAGR of approximately 6.2% from 2025 to 2035.

By Product Type

Traditional Ureteric Stents:

Traditional ureteric stents have been widely used in clinical practice for years. These stents are typically made from materials like silicone and are designed to provide temporary support to the ureters, facilitating urine flow from the kidneys to the bladder. Their established use and cost-effectiveness make them a commonly selected option among healthcare providers. However, traditional stents often pose challenges such as patient discomfort and a higher risk of encrustation and infection. The market's inclination towards more advanced stent types is slowly reducing the share of traditional ureteric stents, but they remain integral in various urological procedures.

Advanced Ureteric Stents:

Advanced ureteric stents incorporate new technologies and materials that enhance their performance and usability. These stents are designed to minimize patient discomfort while reducing the incidence of complications such as encrustation. Many advanced ureteric stents come equipped with features such as anti-reflux valves, which prevent backflow and reduce the risk of infections. The growing preference for these stents is largely due to their efficiency and the improved quality of life they offer to patients. As more clinicians become aware of the benefits of advanced stents, their market share continues to increase significantly.

Coated Ureteric Stents:

Coated ureteric stents are designed with specialized coatings that help reduce friction during insertion and minimize complications associated with prolonged use. These coatings often include antimicrobial agents that decrease the risk of urinary tract infections, which are common after stent placement. The increasing prevalence of infections related to stenting procedures has prompted a shift towards coated solutions, making them more desirable in various clinical settings. Patients benefit from enhanced comfort, reduced pain during stent placement, and lower infection rates, which collectively contribute to their growing popularity in the market.

Drug-Eluting Ureteric Stents:

Drug-eluting ureteric stents are an innovative option that incorporates pharmacological agents within the stent material. These stents are designed to release medications over time, targeting inflammation and preventing encrustation. This unique feature significantly enhances patient outcomes by reducing the need for frequent stent replacements and minimizing the occurrence of complications. As the urology field continues to focus on improving patient outcomes through advanced technologies, drug-eluting stents are likely to play a pivotal role in the ureteric stents market, fostering their adoption in various healthcare settings.

Biodegradable Ureteric Stents:

Biodegradable ureteric stents represent a groundbreaking development in stent technology. These stents are made from materials that gradually dissolve within the body, eliminating the need for a secondary procedure to remove them. This innovative solution addresses some of the major drawbacks associated with traditional stenting, including the discomfort and complications arising from long-term stent placement. The growing interest in biodegradable stents is fueled by the potential for improved patient satisfaction and reduced healthcare costs, positioning them as a competitive option within the ureteric stents market.

By Application

Kidney Stones:

Kidney stones are one of the primary applications for ureteric stents, as they often cause obstruction and severe pain. The presence of a stent allows for the passage of urine past the obstruction, which helps alleviate discomfort and prevent further complications. Given the increasing incidence of kidney stones, driven by lifestyle factors, dietary habits, and rising obesity rates, the demand for ureteric stents in this application is expected to grow significantly. As a result, healthcare providers are increasingly relying on ureteric stenting as a viable treatment option for managing kidney stones, contributing to the overall market growth.

Urinary Strictures:

Urinary strictures, which involve narrowing of the urethra or ureters, are another critical application for ureteric stents. These strictures can result from various factors including injury, inflammation, or previous surgical procedures. Ureteric stents play a vital role in maintaining patency, allowing for normal urine flow and preventing urinary retention. As awareness of urinary strictures increases, alongside the rise in surgical interventions that may lead to strictures, the demand for ureteric stents in this application is anticipated to grow, further propelling the market forward.

Tumors:

In cases where tumors obstruct urinary flow, ureteric stents are essential in managing patient care. These stents are employed to alleviate symptoms and improve quality of life for patients suffering from obstructive uropathy caused by malignancies. The growing incidence of various cancers, coupled with advancements in oncology treatments, is expected to increase the application of ureteric stents in oncological care. As healthcare providers focus on comprehensive patient management, the demand for ureteric stents for tumor-related applications is likely to see considerable growth in the coming years.

Others:

In addition to the primary applications of kidney stones, urinary strictures, and tumors, ureteric stents are also used for various other conditions. This category may include postoperative care following kidney or ureteral surgeries, as well as cases of congenital abnormalities affecting urinary tract function. The versatility of ureteric stents allows for their application in diverse scenarios, contributing to the overall market growth. As advancements in technology continue to emerge, the range of applications for ureteric stents is likely to expand, leading to further market opportunities.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for ureteric stents, as they provide comprehensive care for patients undergoing urological procedures. The availability of specialized medical personnel and advanced surgical facilities makes hospitals a preferred choice for stent placement. The increasing number of hospitals equipped with urology departments and the rise in surgical interventions are driving the demand for ureteric stents through this channel. Moreover, hospitals often serve as the primary point of contact for patients seeking treatment for urological disorders, further solidifying their dominant role in the market.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining prominence as an alternative distribution channel for ureteric stents. These facilities are designed for outpatient procedures, allowing patients to receive care without the need for extended hospital stays. The shift towards outpatient care, driven by the desire for cost-effective and efficient treatment options, has resulted in increased utilization of ASCs for ureteric stenting procedures. As more patients prefer to undergo procedures in an ASC setting, the demand for ureteric stents through this channel is expected to rise, contributing to market growth.

Specialty Clinics:

Specialty clinics focused on urology are also significant players in the distribution of ureteric stents. These clinics offer targeted care for patients with specific urological concerns, enabling healthcare providers to deliver specialized treatment options. The rising preference for personalized care and the growing number of specialty clinics dedicated to urological health further drive the demand for ureteric stents within this channel. The ability of specialty clinics to provide tailored solutions enhances patient satisfaction and contributes to the overall growth of the ureteric stents market.

Online Stores:

Online stores are emerging as an additional distribution channel for ureteric stents, providing convenience for both healthcare providers and patients. The increase in e-commerce and the growing acceptance of online purchasing within the medical supplies sector are driving this trend. Online platforms allow for easy access to a variety of ureteric stents, enabling providers to select the most suitable products for their patients. As e-commerce continues to expand, the growing trend of purchasing medical supplies online is expected to shape the future distribution landscape of ureteric stents.

Others:

This category encompasses various other distribution channels for ureteric stents, including direct sales by manufacturers and distribution through medical supply wholesalers. These alternative channels play a supportive role in meeting the demand for ureteric stents across different healthcare settings. As the ureteric stents market evolves, the diversification of distribution channels will continue to be important in ensuring that stents are readily available for healthcare providers, contributing to improved patient care and outcomes.

By Material Type

Metal:

Metal ureteric stents are known for their durability and are often used in complex cases where prolonged support is necessary. These stents are typically made from materials such as stainless steel or nickel-titanium alloy, which offer strength and flexibility. Metal stents are particularly advantageous for patients with recurrent obstructions, as they are less likely to collapse compared to other materials. However, the potential for discomfort and the risk of encrustation may limit their use in certain patient populations. Overall, metal ureteric stents remain a fundamental option in the market, especially for challenging clinical scenarios.

Silicone:

Silicone ureteric stents are highly biocompatible and are widely used due to their flexibility and comfort. These stents are designed to reduce irritation and discomfort during placement and removal, making them a popular choice for both patients and healthcare providers. Silicone stents are also less prone to encrustation compared to their metal counterparts, which contributes to better patient outcomes. The affordability and ease of use associated with silicone stents further enhance their demand in the ureteric stents market, leading to their prominent presence across various healthcare settings.

Polymer:

Polymer ureteric stents have gained popularity due to their lightweight nature and advanced properties. These stents are designed to be flexible and provide a comfortable fit, minimizing patient discomfort during placement. The use of polymers also enables the incorporation of drug-eluting technologies, which can significantly improve patient outcomes. As the demand for innovative stent solutions grows, polymer ureteric stents are likely to capture a larger market share, driven by their advantages in terms of performance and patient comfort. The ongoing research and development in polymer materials are expected to yield further advancements in stent technology.

Others:

This category includes various other materials utilized in the production of ureteric stents, such as hybrid materials that combine the properties of different substances. The development of novel materials, including those that are biodegradable, is increasing in response to the evolving needs of the healthcare landscape. These innovations aim to address some of the limitations of traditional materials, such as encrustation and patient discomfort. The continuous exploration of new materials is expected to drive growth and diversification in the ureteric stents market, catering to a broader range of patient needs.

By Region

The North American ureteric stents market is anticipated to hold a significant share, with projections estimating it to reach approximately USD 600 million by 2035. This growth can be attributed to the high prevalence of urological disorders, advancements in medical technology, and the presence of well-established healthcare infrastructure. The increasing awareness regarding the availability of advanced stent technologies and the rise in minimally invasive surgical procedures are further propelling market growth in this region. Additionally, the growing geriatric population, which is more susceptible to urinary tract disorders, is expected to contribute to the rising demand for ureteric stents in North America, with a CAGR of around 6.5% during the forecast period.

In Europe, the ureteric stents market is projected to reach approximately USD 450 million by 2035, driven by similar factors influencing the North American market. The region is witnessing a growing focus on urology, with an increase in specialized healthcare facilities and advancements in stent technologies. Moreover, the rising demand for outpatient and minimally invasive procedures is fostering the adoption of ureteric stents in various European countries. Countries such as Germany, the UK, and France are expected to dominate the market, accounting for a significant share due to their robust healthcare systems and increasing investments in urological care.

Opportunities

The ureteric stents market presents numerous opportunities driven by ongoing advancements in medical technology and a rising focus on patient-centered care. As the demand for minimally invasive surgical procedures continues to grow, healthcare providers are increasingly adopting innovative stent solutions that enhance patient outcomes. The development of drug-eluting and biodegradable stents represents a significant opportunity for market players to differentiate their products and improve patient satisfaction. Furthermore, the expansion of healthcare services in emerging economies provides a fertile ground for market growth, as improved access to healthcare enables more patients to seek treatment for urological disorders. Companies that invest in research and development to create next-generation stents are likely to capture a larger share of the market and enhance their competitive positioning.

Additionally, increasing awareness regarding urological health and the significance of early intervention presents opportunities for ureteric stent manufacturers to educate both patients and healthcare providers. Collaborations with healthcare institutions and participation in urological conferences can enhance visibility and facilitate product adoption. The trend towards personalized medicine is also creating openings for tailored stent solutions that address specific patient needs. As the market continues to evolve, proactive companies that leverage these opportunities will be well-positioned to thrive in the competitive landscape of ureteric stents.

Threats

The ureteric stents market faces several challenges, including potential regulatory hurdles and the risk of device-related complications. Regulatory bodies may impose stringent guidelines for the approval and commercialization of new stent technologies, which can hinder product launches and slow down innovation. Furthermore, the potential for complications such as stent-related infections, encrustation, and patient discomfort can deter both healthcare providers and patients from opting for ureteric stenting procedures. As competition in the market intensifies, companies may face price pressure, which can impact profit margins and overall sustainability. Additionally, the emergence of alternative treatment options for urological disorders may pose a threat to the market, necessitating continual advancements and differentiation in stent technologies to maintain market relevance.

Restraining factors also play a role in shaping the market dynamics. High costs associated with advanced stent technologies, particularly in developing regions, may limit access to innovative solutions, hindering market penetration. The lack of trained professionals in some areas can create barriers to the effective use of stents and may result in suboptimal patient outcomes. Additionally, varying reimbursement policies across different regions can impede the affordability and accessibility of ureteric stents, affecting patient decisions to pursue stenting procedures. Addressing these restraining factors will be crucial for stakeholders aiming to capitalize on the growth potential within the ureteric stents market.

Competitor Outlook

• Boston Scientific Corporation
• Medtronic plc
• Cook Medical Incorporated
• Coloplast A/S
• Teleflex Incorporated
• Janssen Pharmaceuticals, Inc.
• B. Braun Melsungen AG
• Smith & Nephew plc
• AngioDynamics, Inc.
• UroGen Pharma Ltd.
• Integra LifeSciences Corporation
• Teleflex Incorporated
• Cordis Corporation
• Olympus Corporation
• Medline Industries, Inc.

The competitive landscape of the ureteric stents market is characterized by the presence of several key players striving to enhance their product offerings and market share. Companies like Boston Scientific Corporation and Medtronic plc are leading the charge with innovative ureteric stent designs and advanced technologies. Boston Scientific, for instance, is known for its extensive portfolio of urological devices, including a range of ureteric stents that incorporate drug-eluting capabilities aimed at reducing complications and improving patient outcomes. Medtronic, on the other hand, emphasizes its commitment to minimally invasive surgical solutions, continually investing in research and development to expand its stent offerings.

Cook Medical Incorporated and Coloplast A/S are also significant competitors in the ureteric stents market, recognized for their focus on patient comfort and stent effectiveness. Cook Medical has developed a variety of ureteric stents that prioritize ease of placement and patient safety. Coloplast, known for its expertise in urological products, offers stents that cater to the unique needs of patients while providing effective solutions for urinary tract management. The presence of such companies enhances the competitive dynamics of the market, fostering innovation while also driving improvements in patient care.

Teleflex Incorporated and Janssen Pharmaceuticals, Inc. further contribute to the competitive landscape with their specialized focus on urological health solutions. Teleflex is recognized for its cutting-edge stent technologies, including coated and drug-eluting options that address the complexities of ureteric stenting. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, is known for its commitment to research and development, focusing on advanced therapies for urological disorders. As the market continues to evolve, these companies and several others will play a pivotal role in shaping the future of the ureteric stents market, ensuring that patient needs remain at the forefront of innovation.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Coloplast A/S
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Medtronic plc
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Cordis Corporation
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Smith & Nephew plc
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 UroGen Pharma Ltd.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AngioDynamics, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Olympus Corporation
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 B. Braun Melsungen AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Teleflex Incorporated
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Medline Industries, Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Cook Medical Incorporated
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boston Scientific Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Janssen Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Integra LifeSciences Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Ureteric Stents Market, By Application
    • 6.1.1 Kidney Stones
    • 6.1.2 Urinary Strictures
    • 6.1.3 Tumors
    • 6.1.4 Others
  • 6.2 Ureteric Stents Market, By Product Type
    • 6.2.1 Traditional Ureteric Stents
    • 6.2.2 Advanced Ureteric Stents
    • 6.2.3 Coated Ureteric Stents
    • 6.2.4 Drug-Eluting Ureteric Stents
    • 6.2.5 Biodegradable Ureteric Stents
  • 6.3 Ureteric Stents Market, By Material Type
    • 6.3.1 Metal
    • 6.3.2 Silicone
    • 6.3.3 Polymer
    • 6.3.4 Others
  • 6.4 Ureteric Stents Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Online Stores
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Ureteric Stents Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Ureteric Stents market is categorized based on

By Product Type

• Traditional Ureteric Stents
• Advanced Ureteric Stents
• Coated Ureteric Stents
• Drug-Eluting Ureteric Stents
• Biodegradable Ureteric Stents

By Application

• Kidney Stones
• Urinary Strictures
• Tumors
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Online Stores
• Others

By Material Type

• Metal
• Silicone
• Polymer
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Boston Scientific Corporation
• Medtronic plc
• Cook Medical Incorporated
• Coloplast A/S
• Teleflex Incorporated
• Janssen Pharmaceuticals, Inc.
• B. Braun Melsungen AG
• Smith & Nephew plc
• AngioDynamics, Inc.
• UroGen Pharma Ltd.
• Integra LifeSciences Corporation
• Teleflex Incorporated
• Cordis Corporation
• Olympus Corporation
• Medline Industries, Inc.